A blood-based biomarker panel can reliably predict biological age-related decline before clinical symptoms appear.
Different aspects of the evidence point in different directions or support competing explanations. State definitions
No evidence has been admitted since this assessment.
Retained questions may have been narrowed or reframed by the current assessment.
Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.
Normal Record Review is the Observatory’s assessment process for newly considered evidence, not external scientific peer review. LPR identifies an internal source-review record. RN identifies an institutional note. PROG identifies a programme: AI (Artificial Intelligence), AM (Advanced Materials), BT (Biotechnology), or QE (Quantum Engineering).
How the claim could hold, what obstructs it, and possible ways forward. The State Warrant above remains the authoritative current assessment.
Blood panel as proxy for future individual decline. Oh et al. (2023) show that organ-enriched plasma proteins yield organ-specific age estimates associated with disease and mortality; their 2025 UK Biobank analysis adds prospective organ-related disease and mortality associations, including information beyond selected established biomarkers for mortality. The unresolved measurement question is externally calibrated, transportable absolute risk for a defined asymptomatic individual's particular later decline, with useful discrimination and incremental value against appropriate clinical predictors for each outcome. Cohort hazard associations do not by themselves establish dependable patient-level predictions or a beneficial clinical decision. This remains a proxy-measurement bottleneck in the sense of RN-005.
Validation requires longitudinal follow-up and transportability testing. The 2025 UK Biobank analysis provides substantial baseline-to-outcome follow-up, so a categorical absence of longitudinal evidence is no longer accurate. Disease-specific absolute-risk calibration, performance in independent clinical populations and across assays, and the consequences of clinical decisions still require long-horizon validation. This biological-time lag compounds BN-001: cohort associations can be established before a panel is reliable and useful for a particular patient's pre-symptomatic decision.
A recorded possible resolution path, not automatically a sufficient test for closing the claim.
Externally validated organ-specific absolute-risk prediction and individual trajectory modelling. Organ-enriched plasma-protein models now show prospective associations with incident disease and mortality in a large UK Biobank cohort. The next resolution step is an independently validated, pre-symptomatic panel that gives calibrated risks for specified decline pathways in individual patients, adds useful discrimination beyond relevant clinical predictors across settings and assays, and has an appropriate decision boundary. Multi-omic and repeated-measure designs may help, but another organ-age estimate or cohort hazard ratio alone does not complete this attractor.
Assessments on the same date follow their assessment ID order. An evidence-basis correction and a review of new evidence can be separate events.
Historical narrative recorded for this claim. It does not override the current State Warrant.
Questions retained in this record. The current State Warrant may have narrowed or reframed them. Recorded dates refer to question history, not necessarily the age of the current wording; known revision dates are shown separately.
Given Oh et al.'s organ-specific plasma-protein signals, can a defined baseline blood panel predict a particular asymptomatic individual's future decline pathway with reliable calibration and incremental value over clinical risk factors?
Question recorded 2024-01-15Which commercial assay deployments, if any, are sufficiently specific to the blood-panel claim to count as anticipatory institutional evidence? The former seventh-occurrence count included saliva and cheek-swab products and is withdrawn; company-funded validation still warrants independent scrutiny.
Question recorded 2024-01-15FR-BT-0003 is the third record in PROG-BT, and measurement validity pressure has now appeared in all three. Is this the diagnostic signal that transforms the PROG-BT tendency into a full programme diagnosis? Or does the Observatory require more records before naming the diagnosis?
Question recorded 2024-01-15| Mutation | Date | Field | Prior value | Current value |
|---|---|---|---|---|
| M-010 | 2026-10-19 | Source reviewprovenance_review | LPR-001-D27 | LPR-001-D55What this update recorded for M-010Second-cycle Legacy Provenance Review completed as PASS across all six existing evidence instances. Underlying sources and claim representation verified; existing structured provenance is sufficient and no unverifiable attribution was introduced. No factual, interpretive, attribution, or verification-stage discrepancy identified. Wang et al. (bioRxiv, 2026) was identified as genuinely new evidence relevant to individual predictive uncertainty and is held outside LPR-001 for Normal Record Review. Canonical outcome verified / not_required; Pressure State and Verification Stage unchanged. |
| M-009 | 2026-10-19 | Assessment correctionassessment_correction | AS-003 / FRAGMENTING / VS-03 | AS-004 / FRAGMENTING / VS-04What this update recorded for M-009Operator-ratified stage and scope reconciliation. VS-04 concerns reproduced population-level predictive associations under the explicitly qualified July interpretation; it does not certify calibrated individual prognosis or clinical utility. The retained longitudinal clock-validation packet survives September corrections. No general cohort/team equivalence rule, new evidence or Pressure State transition. Preserve AS-001–AS-003 and July AS-001 overlay. Receipt: docs/reviews/AM-0004-BT-0003-STAGE-RECONCILIATION-2026-10-19.md. |
| M-008 | 2026-09-25 | Record reviewrecord_review | LPR-001-D27 held 2025 organ-proteomics candidate | IN-006 admitted; AS-003 reaffirmed FRAGMENTING / VS-03What this update recorded for M-008Normal Record Review admitted Oh et al., Nature Medicine 2025, DOI 10.1038/s41591-025-03798-1, with structured primary provenance. In 44,498 UK Biobank participants, 11 organ-specific age estimates derived from 2,916 plasma proteins were associated with subsequent disease and mortality over 2–17 years. This strengthens prospective organ-specific blood evidence beyond the 2023 study but does not establish externally calibrated individual absolute risk, transportable performance or clinical benefit from acting on a score. AS-003 appended with no pressure-state or stage transition. BN-001, RM-001 and AT-001 sharpened; lineage extended. LPR-001-D27 marker and historical assessments retained unchanged. |
| M-007 | 2026-09-25 | Source or history correctionprovenance_correction | LPR-001-D27 discrepancies_found / pending | LPR-001-D27 discrepancies_corrected / completedWhat this update recorded for M-007Approved bounded correction of IN-002 through IN-005. Lehallier's cross-sectional age-associated plasma proteome was separated from prospective outcome claims; Ahadi ageotypes distinguished from Oh's organ-specific plasma-protein models; DunedinPACE dated to 2022 with group-level outcome associations distinguished from clinical utility; InnerAge blood, Index saliva and TallyAge cheek-swab specimens corrected. IN-001 remained as audited. AS-001 preserved and AS-002 appended. BN-001, AT-001, lineage and OQ-001/OQ-002 aligned where they repeated withdrawn premises. FRAGMENTING / VS-03 retained on the narrower individual prospective-validation question. No 2025+ scientific evidence admitted. |
| M-006 | 2026-09-06 | Description restoreddescription_restored | Legacy ingestion cutoffs: mechanisms:BN-001, mechanisms:RM-001, mechanisms:AT-001 | Source-restored complete descriptionsWhat this update recorded for M-006Editorial Correction (GP-001), RENDER-PILOT-001 content restoration: restored BN-001, RM-001, AT-001 from FR_BT_0003_biological_age_biomarker_prediction.html (Drive file 1JK_i4ftSrQ5UtZWm2Ncv8sd8wykgIaC0). Each damaged value was a verified prefix of the recovered source after the existing FR-MF to FR-AM identifier migration. Restored the omitted remainder using the original converter text normalization; no inferred completion. Existing later corrections retained. Restoration recovers historical wording and does not reaffirm it as the current assessment. Assessments, evidence instances, open questions, claim, status and rendering eligibility unchanged. Source hashes and field receipt: docs/reviews/render-pilot-content-restoration.json; current-assessment compatibility review: docs/reviews/RENDER-PILOT-001-CONTENT-RESTORATION.md. |
| M-005 | 2024-01-15 | Rn 005 condition confirmedrn_005_condition_confirmed | — | RN-005-CONDITION-CONFIRMED |
| M-004 | 2024-01-15 | Mechanisms recordedmechanisms_recorded | — | MECHANISMS-RECORDED |
| M-003 | 2024-01-15 | Assessment issuedassessment_issued | — | ASSESSMENT-ISSUED |
| M-002 | 2024-01-15 | Instances loggedinstances_logged | — | INSTANCES-LOGGED |
| M-001 | 2024-01-15 | Record createdrecord_created | — | RECORD-CREATED |
Logged entries are reports on record, not counts of independent studies or patients. Several entries can concern the same underlying evidence. Supportive and Contesting describe an entry’s relation to the claim. Partial indicates limited or mixed bearing; read the details for limitations or legacy status. These labels are not study-quality ratings.
Steve Horvath (2013, Genome Biology) publishes the first multi-tissue epigenetic clock, demonstrating that DNA methylation patterns predict chronological age with high accuracy (r ≈ 0.96 across tissues). Subsequent clocks — Hannum (2013), PhenoAge (2018), GrimAge (2019) — improve predictive performance for biological outcomes including mortality, disease incidence, and functional decline. GrimAge in particular demonstrates that accelerated epigenetic age (epigenetic age exceeding chronological age) predicts mortality risk independently of other known risk factors. These results establish that blood-based methylation measurements have predictive validity for biological outcomes — epigenetic age acceleration predicts who will decline faster. The clocks are not purely blood-based in all cases, but blood methylation profiles drive the most practically deployable versions. This is the strongest positive evidence in the record: longitudinal cohort data demonstrating that the measurement predicts subsequent clinical outcomes.
Lehallier et al. (2019, Nature Medicine) measured 2,925 plasma proteins in 4,263 people aged 18–95 and identified nonlinear, age-associated waves of protein change. The analysis linked these patterns to biological pathways and age-related disease traits, establishing that blood proteomics carries substantial age-related information. This study did not show that its protein panel prospectively predicted mortality, frailty or disease incidence, nor that it outperformed epigenetic clocks. Such outcome-prediction claims require separate longitudinal validation. Oh et al.'s later organ-specific analysis is recorded separately in IN-003.
Ahadi et al. (2020) followed 106 people with deep longitudinal multiomics measurements and identified differing molecular ageotypes involving metabolic, immune, liver and kidney pathways. This is evidence of individual pathway heterogeneity, not a direct measure of each organ's biological age. Oh et al. (2023) then used organ-enriched plasma proteins to build age models for 11 organs across five cohorts; accelerated age in one organ was common, and organ-age estimates related to organ-specific disease and mortality risk. That result demonstrates that blood can carry organ-specific signals. The remaining question is how reliably a particular panel forecasts an asymptomatic individual's later, specific decline beyond existing clinical risk information. Heterogeneity alone does not establish that blood panels fail.
Belsky et al. (2022, eLife) derived DunedinPACE, a single-sample blood DNA-methylation measure trained on two decades of longitudinal change in multiple organ-system indicators. Across validation analyses it was associated with morbidity, disability and mortality; its effect sizes were similar to GrimAge and it added incremental prediction beyond GrimAge in analyses of incident outcomes. These are group-level validation results, not proof of an individually effective treatment selected from the score. The separate clinical-utility question is whether acting on a result improves a person's health outcome. That interpretation should not be attributed to the paper as a newly discovered empirical failure.
The named consumer products use different specimens and measurements: InsideTracker InnerAge uses blood biomarkers, Elysium Index profiles DNA methylation from saliva, and TallyAge profiles DNA methylation from a cheek swab. Their availability establishes commercial interest in biological-age testing, but the saliva and cheek-swab offerings are not blood-based panels and cannot be counted as deployments satisfying this record's blood-panel claim. Product marketing does not validate prospective, individual-level prediction of decline. The former seventh-occurrence classification as claim-specific anticipatory evidence is therefore withdrawn pending a stricter comparison of the actual assays and claims.
Oh et al. (Nature Medicine, 2025) estimated ages of 11 organs from 2,916 plasma proteins in 44,498 UK Biobank participants. Baseline organ age gaps were associated with incident age-related diseases and all-cause mortality over 2–17 years of follow-up. An especially aged brain was associated with later Alzheimer's disease (HR 3.11, adjusted for age, sex and APOE genotype); brain and immune-system age estimates also carried mortality information. Mortality associations persisted after adjustment for PhenoAge and cystatin C. This is substantial prospective cohort evidence for organ-specific signals in blood, extending the team's 2023 organ-age work with a larger cohort and explicit incident-disease analyses. It is an observational risk-association result: the study does not establish externally calibrated absolute risk for a particular asymptomatic patient, the effect of acting on a score, or a proven intervention that changes outcomes.